NCCN 2020 Virtual Congress: Hematologic Malignancies

Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients

October 11, 2020

During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.

Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis

October 11, 2020

During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.

Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma

October 11, 2020

In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.

Hot Topics of Discussion in the Management of Multiple Myeloma

October 11, 2020

Jens Hillengass, MD, discusses the key takeaways from his presentation at the 2020 National Comprehensive Cancer Network Virtual Congress: Hematologic Malignancies, in which he shared his insights on the diagnostic and staging criteria in multiple myeloma.

Targeted Therapies Offer New Treatment Options for R/R MZL Across Subtypes

October 10, 2020

Marginal zone lymphomas are a heterogenous group of B-cell non-Hodgkin lymphomas based on their etiology and clinical presentation, and as such, treatment for these diseases vary by subtype, according to Stephen Douglas Smith, MD.

Management of Early Stage Hodgkin Lymphoma Requires “Balancing” Individual Risk

October 10, 2020

When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.